Soliris Filing Planned In Second-Half Of 2006; "TRIUMPH" Pivotal Aptly Named?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion plans to submit its biologic Soliris for treatment of paroxysmal nocturnal hemoglobinuria in the U.S. and EU in the second half of 2006